Penumbra, Inc. (NYSE:PEN) Director Bridget O’rourke Sells 50 Shares of Stock

Penumbra, Inc. (NYSE:PEN) Director Bridget O’rourke sold 50 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $285.48, for a total transaction of $14,274.00. Following the transaction, the director now directly owns 5,573 shares of the company’s stock, valued at $1,590,980.04. This trade represents a 0.89 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Penumbra Trading Up 0.8 %

NYSE PEN opened at $285.91 on Thursday. The firm has a market cap of $11.01 billion, a PE ratio of 840.91, a price-to-earnings-growth ratio of 2.83 and a beta of 0.53. Penumbra, Inc. has a 52 week low of $148.00 and a 52 week high of $310.00. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average price of $265.94 and a 200 day moving average price of $234.26.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The firm had revenue of $315.52 million during the quarter, compared to analyst estimates of $311.63 million. As a group, sell-side analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on PEN. Canaccord Genuity Group boosted their price target on shares of Penumbra from $323.00 to $340.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. UBS Group raised their price objective on Penumbra from $305.00 to $320.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. StockNews.com lowered shares of Penumbra from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. Robert W. Baird upped their price target on shares of Penumbra from $305.00 to $328.00 and gave the company an “outperform” rating in a report on Wednesday, February 19th. Finally, Truist Financial raised their price target on Penumbra from $285.00 to $325.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $292.64.

Institutional Investors Weigh In On Penumbra

Several institutional investors have recently added to or reduced their stakes in PEN. Employees Retirement System of Texas grew its position in Penumbra by 31.9% during the 4th quarter. Employees Retirement System of Texas now owns 5,273 shares of the company’s stock worth $1,252,000 after purchasing an additional 1,274 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in Penumbra during the fourth quarter valued at $760,000. Polar Asset Management Partners Inc. boosted its stake in shares of Penumbra by 10.5% in the fourth quarter. Polar Asset Management Partners Inc. now owns 122,126 shares of the company’s stock worth $29,002,000 after buying an additional 11,605 shares during the last quarter. Cache Advisors LLC purchased a new position in Penumbra during the fourth quarter valued at approximately $534,000. Finally, Public Employees Retirement System of Ohio lifted its holdings in Penumbra by 6.2% in the fourth quarter. Public Employees Retirement System of Ohio now owns 22,399 shares of the company’s stock valued at $5,319,000 after acquiring an additional 1,316 shares during the period. Institutional investors and hedge funds own 88.88% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.